瑞博生物-B(06938.HK):核心产品VORTOSIRAN针对CAD的2A期积极研究结果

智通财经
Jul 22
【瑞博生物-B(06938.HK):核心产品VORTOSIRAN针对CAD的2A期积极研究结果】智通财经APP讯,瑞博生物-B(06938.HK)发布公告,公司在上海举行的大国新药全球会议上公布了在欧洲进行的评估vortosiran (RBD4059)(靶向凝血因子XI (FXI) 的小干扰RNA (siRNA)疗法)针对慢性冠状动脉疾病(CAD)患者的2a期研究的积极结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10